Cytochrome P4501A2: Enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels

Cancer Epidemiology Biomarkers and Prevention

Volumn 5, Issue 9, 1996, Pages 693-698

  Landi, Maria Teresa ^a   Zocchetti, Carlo ^b   Bernucci, Ilaria ^a   Kadlubar, Fred F ^d   Tannenbaum, Steven ^e   Skipper, Paul ^e   Bartsch, Helmut ^f   Malaveille, Christian ^g   Shields, Peter ^h   Caporaso, Neil E ^h   Vineis, Paolo ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b PARKINSON INSTITUTE   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BIPHENYLAMINE; CYTOCHROME P450 ISOENZYME; HEMOGLOBIN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLADDER CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; COFFEE; CONTROLLED STUDY; DNA ADDUCT; ENZYME INDUCTION; GENETIC SUSCEPTIBILITY; HUMAN; MALE; MEAT; NORMAL HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; XENOBIOTIC METABOLISM;

AGE FACTORS; ALCOHOL DRINKING; AMINOBIPHENYL COMPOUNDS; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CARCINOGENS; COFFEE; CYTOCHROME P-450 CYP1A2; DNA ADDUCTS; DRINKING; ENZYME INDUCTION; GLUTATHIONE TRANSFERASE; HEMOGLOBINS; HUMANS; MALE; MEAT; MIDDLE AGED; OXIDATION-REDUCTION; PHENOTYPE; PLANTS, TOXIC; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING; THEOPHYLLINE; TOBACCO; URIC ACID; URINARY BLADDER NEOPLASMS;

EID: 16044367886     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Butler, M. A., Lang, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J. P., Lawsen, M. F., and Kadlubar, F. F. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics, 2: 116-127, 1992.
2. Nakajima, M., Yokoi, T., Mizutani, M., Shin, S., Kadlubar, F. F., and Kamataki, T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites; absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol., Biomarkers & Prev., 3: 413-421, 1994.
3. Kalow, W., and Tang, B. K. The use of caffeine for enzyme assays: a critical appraisal. Clin. Pharmacol. & Ther., 53: 503-514, 1993.
4. Lang, N. P., Butler, M. A., Massengill, J., Lawson, M., Stotts, R. C., Hauer-Jensen, M., and Kadlubar, F. F. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol., Biomarkers & Prev., 3: 675-682, 1994.
5. Butler, M. A., Iwasaki, M., Guengerich, F. P., and Kadlubar, F. F. Human cytochrome P-450PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. USA, 86: 7697-7700, 1989.
6. International Agency for Research on Cancer. Chemicals, industrial processes and industries associated with cancer in humans. IARC Monogr. Eval. Carcinog. Risks. Hum., 1-29 (Suppl. 4): 37-38, 1982.
7. Beland, F. A., and Kadlubar, F. F. Factor involved in the induction of urinary bladder cancer by aromatic amines. Banbury Rep., 23: 315-326, 1986.
8. Kato, S., Bowman, E. D., Harrington, A. M., Blomeke, B., and Shields, P. G. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J. Natl. Cancer Inst., 87: 902-907, 1995.
9. Gaylor, D. W., Kadlubar, F. F., and Beland, F. A. Application of biomarkers to risk assessment. Environ. Health. Perspect., 98: 139-141, 1993.
10. Lambert, G. H., Schoeller, D. A., Kotake, A. N., Flores, C., and Hay, D. The effect of age, gender, and sexual maturation on the caffeine breath test. Dev. Pharmacol. Ther., 9: 375-388, 1986.
11. Kalow, W., and Tang, B. K. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin. Pharmacol. & Ther., 50:508-519, 1991.
12. Vineis, P., Bartsch, H., Caporaso, N., Harrington, A. M., Kadlubar, F. F., Landi, M. T., Malaveille, C., Shields, P. G., Skipper, P., Talaska, G., and Tannenbaum, S. R. Genetically based N-acetyltransferase metabolic polymorphism and low level environmental exposure to carcinogens. Nature (Lond.), 369: 154-156, 1994.
13. Malaveille, C., Vineis, P., Esteve, J., Ohshima, H., Brun, G., Hautefeuille, A., Gallet, P., Ronco, G., Terracini, B., and Bartsch, H. Levels of mutagens in the urine of smokers of black and blond tobacco correlate with their risk of bladder cancer. Carcinogenesis (Lond.), 10: 577-586, 1989.
14. Grant, D. M., Tang, B. K., and Kalow, W. Variability in caffeine metabolism. Clin. Pharmacol. & Ther., 33: 591-602, 1983.
15. Bryant, M. S., Skipper, P. L., Tannenbaum, S. R., and Maclure, M. Hemoglobin adducts of 4-aminobiphenyl in smokers and nonsmokers. Cancer Res., 47: 602-608, 1987.
16. Shields, P. G., Bowman, E. D., Harrington, A. M., Doan, V. T., and Weston, A. Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res., 53: 3486-3492, 1993.
17. SAS Institute, Inc. SAS/STAT User's Guide, Release 6.03. Cary, NC: SAS Institute, Inc., 1988.
18. Snedecor, G. W., and Cochran, W. G. Statistical Methods, Ed. 7, Chaps. 12, 14, 16. Ames, Iowa: Iowa State University Press, 1982.
19. Axelson, O., Fredriksson, M., and Ekberg K. Use of the prevalence ratio v prevalence odds ratio as a measure of risk in cross sectional studies. Occup. Environ. Med., 51: 574, 1994.
20. Rothman, K. J. Modern Epidemiology. Boston: Little, Brown, and Co., 1986.
21. Lee, J. Odds ratio or relative risk for cross-sectional data? Int. J. Epidemiol., 23: 201-203, 1994.
22. Greenland S. Interpretation and choice of effect measures in epidemiologic analyses. Am. J. Epidemiol., 24: 1066-1067, 1995.
23. Bartsch, H., Caporaso, N., Coda, M., Kadlubar, F., Malaveille, C., Skipper, P., Talska, G., Tannenbaum, S. R., and Vineis, P. Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J. Natl. Cancer Inst., 82: 1826-1831, 1990.
24. Eaton, D. L., Gallagher, E. P., Bammler, T. K., and Kunze, K. L. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics, 5: 259-274, 1995.
25. Kadlubar, F. F., Talaska, G., Butler, M. A., Teitel, C. H., Hassengill, J. P., and Lang, N. P. Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites. In: M. L. Mendelsohn and R. J. Albertini (eds.), Mutation and the Environment. Part B: Metabolism, Testing Methods, and Chromosomes, pp. 107-114. New York: John Wiley & Sons, Inc., 1990.
26. Campbell, M. E., Spielberg, S. P., and Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin. Pharmacol. & Ther., 42:157-165, 1987.
27. Tang, B. K., Zhou, Y., Kadar, D., and Kalow, W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics, 4: 117-124, 1994.
28. Birkett, D. J., and Miners, J. O. Caffeine renal clearance and urine caffeine concentrations during steady state dosing. Implications for monitoring caffeine intake during sports events. Br. J. Clin. Pharmacol., 31: 405-408, 1991.
29. Hoffmann, D., Brunnemann, K. D., Adams, J. D., and Hecht, S. S. Formation and analysis of N-nitrosamines in tobacco products and their endogenous formation in consumers. In: I. K. O'Neill, R. C. von Borstel, C. T. Miller, J. Long, and H. Bartsch (eds.), N-Nitroso Compounds: Occurrence, Biological Effects and Relevance to Human Cancer, pp. 743-762. IARC Scientific Publ. No. 57. Lyon, France: IARC, 1984.
30. International Agency for Research on Cancer. Tobacco smoking. IARC Monogr. Eval. Carcinog. Risks. Hum., 38: 83-126, 1986.
31. Guengerich, F. F. Metabolic activation of carcinogens. Pharmacol. & Ther. 54: 16-61, 1992.
32. Lofroth, G., and Rannug, A. Ah receptor ligands in tobacco smoke. Toxicol. Lett. 42: 131-136, 1988.
33. Horn, E. P., Tucker, M. A., Lambert, G., Silverman, D., Zametkin, D., Sinha, R., Hartge, T., Landi, M. T., and Caporaso, N. E. A. Study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiol., Biomarkers & Prev., 4: 529-533, 1995.
34. Vineis, P. Hypothesis: coffee consumption, N-acetyltransferase phenotype, and cancer. J. Natl. Cancer Inst., 85: 1004-1005, 1993.
35. International Agency for Research on Cancer. Coffee, tea, mate, methylxanthines and methylglyoxal. IARC Monogr. Eval. Carcinog. Risks. Hum., 51: 291-357, 1991.
36. Anderson, K. E., Conney, A. H., and Kappas, A. Nutrition and oxidative drug metabolism in man: relative influence of dietary lipids, carbohydrate, and protein. Clin. Pharmacol. & Ther., 26: 493-503, 1979.
37. Sinha, R., Rothman, N., Brown, E. D., Mark, S. D., Hoover, R. H., Caporaso, N. E., Levander, O. A., Knize, M. G., Lang, N. P., and Kadlubar, F. F. Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans. Cancer Res., 54: 6154-6159, 1994.
38. Conney A. H. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture. Cancer Res., 42: 4875-4917, 1982.
39. Olsen, J. H., Wallin, H., Boice, J. D., Rask, K., Schulgen, G., and Fraumeni, J. F. Phenobarbital, drug metabolism, and human cancer. Cancer Epidemiol., Biomarkers & Prev., 2: 449-452, 1993.
40. Cartwright, R. A., Adib, R., Appleyard, I., Glashan, R. W., Gray, B., Hamilton-Stewart, P. A., Robinson, M., and Barham-Hall, D. Cigarette smoking and bladder cancer: an epidemiological inquiry in West Yorkshire. J. Epidemiol. Community Health, 37: 256-263, 1983.
41. Morrison, A. S., Buring, J. E., Verhoek, W. G., Aoki, K., Leek, I., Ohno, Y., and Obata, K. An international study of smoking and bladder cancer. J. Urol., 131: 650-654, 1984.
42. Vineis, P., Esteve, J., and Terracini, B. Bladder cancer and smoking in males: types of cigarettes, age at start, effect of stopping and interaction with occupation. Int. J. Cancer, 34: 165-170, 1984.
43. Caporaso, N., Landi, M. T., and Vineis, P. Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics, 1: 4-19, 1991.
44. Nakachi, K., Imai, K., Hayashi, S., Watanabe, J., and Kawajiri, K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res., 57: 5177-5180, 1991.
45. Nakachi, K., Imai, K., Hayashi, S., and Kawajiri, K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res., 53: 2994-2999, 1993.
46. Taioli, E., Crofts, F., Trachman, J., Demopoulos, R., Toniolo, P., and Garte, S. J. A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of the lung. Cancer Res., 55: 472-473, 1995.
47. Yu, M. C., Ross, R. K., Chan, K. K., Henderson, B. E., Skipper, P. L., Tannenbaum, S. R., and Coctzee, G. A. Glutathione S-transferase MI genotype affects aminobiphenyl-hemoglobin adducts levels in white, black, and Asian smokers and nonsmokers. Cancer Epidemiol., Biomarkers & Prev., 4: 861-864, 1995.